Literature DB >> 3479440

Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.

M S Weintraub1, S Eisenberg, J L Breslow.   

Abstract

Apolipoprotein E (apo E) plays an important role in receptor mediated clearance of lipoprotein particles from plasma. Common genetic variation in apo E exists with three alleles coding for proteins called E2, E3, and E4. In in vitro receptor binding assays, E2 binds poorly, whereas E3 and E4 function normally. Recently, the apo E phenotype has been shown to have an effect on low density lipoprotein (LDL) cholesterol levels with levels in subjects with E2 lower and E4 higher than E3. We have examined the effect of the apo E polymorphism on dietary fat clearance using the vitamin A-fat loading test, which specifically labels intestinally derived lipoproteins with retinyl palmitate (RP). 27 normal subjects were studied, 10 with E3/3, 9 with E3/2, 7 with E4/3, and 1 with E4/4. After a vitamin A-containing fatty meal, postprandial RP concentrations were measured in chylomicron (Sf greater than 1,000) and nonchylomicron (Sf less than 1,000) fractions for 14 h. Compared with E3/3 subjects, E3/2 subjects had a significantly higher nonchylomicron RP concentration (P less than 0.05) (peak heights and areas below the curves) indicating slower clearance and the E4/3, E4/4 group had a significantly lower nonchylomicron RP concentration (P less than 0.05) indicating faster clearance. The clearance in the latter group was twice that of E3/2 subjects (P less than 0.01). Thus, heterozygosity for the defective form of apo E, E2, delays, and the surprising presence of a functionally normal allele, E4, increases clearance. This apo E effect on exogenous fat clearance may explain the recently described effect of the apo E phenotypes on LDL cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3479440      PMCID: PMC442425          DOI: 10.1172/JCI113243

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III.

Authors:  G Utermann; K H Vogelberg; A Steinmetz; W Schoenborn; N Pruin; M Jaeschke; M Hees; H Canzler
Journal:  Clin Genet       Date:  1979-01       Impact factor: 4.438

2.  Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components.

Authors:  V G Shore; B Shore
Journal:  Biochemistry       Date:  1973-01-30       Impact factor: 3.162

3.  Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. Identity with the chylomicron remnant transport process.

Authors:  B C Sherrill; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1980-03-10       Impact factor: 5.157

4.  Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat.

Authors:  F Shelburne; J Hanks; W Meyers; S Quarfordt
Journal:  J Clin Invest       Date:  1980-03       Impact factor: 14.808

5.  Human intestinal lipoproteins. Studies in chyluric subjects.

Authors:  P H Green; R M Glickman; C D Saudek; C B Blum; A R Tall
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

6.  HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study.

Authors:  W P Castelli; J T Doyle; T Gordon; C G Hames; M C Hjortland; S B Hulley; A Kagan; W J Zukel
Journal:  Circulation       Date:  1977-05       Impact factor: 29.690

7.  Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man.

Authors:  G Utermann; N Pruin; A Steinmetz
Journal:  Clin Genet       Date:  1979-01       Impact factor: 4.438

8.  Delayed clearance of chylomicron remnants following vitamin-A-containing oral fat loads in broad-beta disease (type III hyperlipoproteinemia).

Authors:  W R Hazzard; E L Bierman
Journal:  Metabolism       Date:  1976-07       Impact factor: 8.694

9.  Chylomicron clearance in normal and hyperlipidemic man.

Authors:  S M Grundy; H Y Mok
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

10.  Simultaneous determination of retinol and retinyl esters in serum or plasma by reversed-phase high-performance liquid chromatography.

Authors:  M G DeRuyter; A P De Leenheer
Journal:  Clin Chem       Date:  1978-11       Impact factor: 8.327

View more
  61 in total

Review 1.  Postprandial lipemia and coronary risk.

Authors:  W Patsch; H Esterbauer; B Föger; J R Patsch
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

2.  Hypercholesterolemia and Dyslipidemia.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

Review 3.  Postprandial lipemia and cardiovascular disease.

Authors:  Dianne Hyson; John C Rutledge; Lars Berglund
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

4.  Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects.

Authors:  D C Rubinsztein; J C Cohen; G M Berger; D R van der Westhuyzen; G A Coetzee; W Gevers
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

5.  Apolipoprotein B RNA editing enzyme-deficient mice are viable despite alterations in lipoprotein metabolism.

Authors:  J R Morrison; C Pászty; M E Stevens; S D Hughes; T Forte; J Scott; E M Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 6.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 7.  Pharmacogenetics of target genes across the warfarin pharmacological pathway.

Authors:  Suman Lal; Srinivasa Rao Jada; Xiaoqiang Xiang; Wan-Teck Lim; Edmund J D Lee; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Elevated triglyceride-rich lipoproteins in diabetes. A study of apolipoprotein B-48.

Authors:  A Curtin; P Deegan; D Owens; P Collins; A Johnson; G H Tomkin
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

9.  Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients.

Authors:  Suman Lal; Edwin Sandanaraj; Srinivasa Rao Jada; Ming-Chai Kong; Lai-Heng Lee; Boon-Cher Goh; Soo-Chin Lee; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

10.  APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population.

Authors:  Rafael O Alvim; Silvia R S Freitas; Noely E Ferreira; Paulo C J L Santos; Roberto S Cunha; José G Mill; José E Krieger; Alexandre C Pereira
Journal:  Lipids Health Dis       Date:  2010-11-08       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.